{
    "Trade/Device Name(s)": [
        "Wondfo Amphetamine Urine Test",
        "Wondfo Secobarbital Urine Test",
        "Wondfo Oxazepam Urine Test"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K121987",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020771"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ",
        "DIS",
        "JXM"
    ],
    "Summary Letter Date": "June 18, 2012",
    "Summary Letter Received Date": "July 6, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3100",
        "21CFR862.3150",
        "21CFR862.3170"
    ],
    "Regulation Name(s)": [
        "Amphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine",
        "Secobarbital",
        "Oxazepam"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Cup",
        "Dip card"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow immunoassay",
        "Competitive binding"
    ],
    "Methodologies": [
        "Immunoassay principles",
        "Antigen-antibody interactions"
    ],
    "Submission Type(s)": [
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for Wondfo Amphetamine, Secobarbital, and Oxazepam Urine Tests using immunochromatographic lateral flow assay for qualitative detection of drugs in urine",
    "Indications for Use Summary": "Intended for qualitative determination of d-Amphetamine, Secobarbital, and Oxazepam at specific cut-off concentrations in human urine samples for healthcare professional and over-the-counter use",
    "fda_folder": "Toxicology"
}